Evidence map›Paper›PMID 24833342›Full record

ArticleBiology2014

Automated sample preparation platform for mass spectrometry-based plasma proteomics and biomarker discovery.

Vilém Guryča, Daniel Roeder, Paolo Piraino, Jens Lamerz, Axel Ducret, Hanno Langen, Paul Cutler

Open access · goldAbstract read
In one paragraph

Article in Biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Vilém GuryčaF. Hoffmann-La Roche Ltd., Pharma Research and Early Development (pRED), Translational Technologies and Bioinformatics, 124 Grenzacherstrasse, Bldg. 93/4.38, 4070 Basel, Switzerland. vilem.guryca@roche.com.
Daniel RoederF. Hoffmann-La Roche Ltd., Pharma Research and Early Development (pRED), Translational Technologies and Bioinformatics, 124 Grenzacherstrasse, Bldg. 93/4.38, 4070 Basel, Switzerland. daniel.roeder@roche.com.
Paolo PirainoF. Hoffmann-La Roche Ltd., Pharma Research and Early Development (pRED), Translational Technologies and Bioinformatics, 124 Grenzacherstrasse, Bldg. 93/4.38, 4070 Basel, Switzerland. ppiraino@gmail.com.
Jens LamerzF. Hoffmann-La Roche Ltd., Pharma Research and Early Development (pRED), Translational Technologies and Bioinformatics, 124 Grenzacherstrasse, Bldg. 93/4.38, 4070 Basel, Switzerland. jens.lamerz@roche.com.
Axel DucretF. Hoffmann-La Roche Ltd., Pharma Research and Early Development (pRED), Translational Technologies and Bioinformatics, 124 Grenzacherstrasse, Bldg. 93/4.38, 4070 Basel, Switzerland. axel.ducret@roche.com.
Hanno LangenF. Hoffmann-La Roche Ltd., Pharma Research and Early Development (pRED), Translational Technologies and Bioinformatics, 124 Grenzacherstrasse, Bldg. 93/4.38, 4070 Basel, Switzerland. hanno.langen@roche.com.
Paul CutlerF. Hoffmann-La Roche Ltd., Pharma Research and Early Development (pRED), Translational Technologies and Bioinformatics, 124 Grenzacherstrasse, Bldg. 93/4.38, 4070 Basel, Switzerland. paul.cutler@roche.com.
Roche (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The identification of novel biomarkers from human plasma remains a critical need in order to develop and monitor drug therapies for nearly all disease areas. The discovery of novel plasma biomarkers is, however, significantly hampered by the complexity and dynamic range of proteins within plasma, as well as the inherent variability in composition from patient to patient. In addition, it is widely accepted that most soluble plasma biomarkers for diseases such as cancer will be represented by tissue leakage products, circulating in plasma at low levels. It is therefore necessary to find approaches with the prerequisite level of sensitivity in such a complex biological matrix. Strategies for fractionating the plasma proteome have been suggested, but improvements in sensitivity are often negated by the resultant process variability. Here we describe an approach using multidimensional chromatography and on-line protein derivatization, which allows for higher sensitivity, whilst minimizing the process variability. In order to evaluate this automated process fully, we demonstrate three levels of processing and compare sensitivity, throughput and reproducibility. We demonstrate that high sensitivity analysis of the human plasma proteome is possible down to the low ng/mL or even high pg/mL level with a high degree of technical reproducibility.

Identifiers

PMID24833342
PMCPMC4009759
OpenAlexW1976487853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.